Verici DX Logo

Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule (“CLFS”) payment rate of $2,650 established through the “gapfill” process for both Tutivia™ (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava™ (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.

Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "We are pleased that the pricing for both Tutivia™ and Clarava™ has been confirmed and finalised at the proposed rates. This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians."

Read full announcement